Breast Cancer Clinical Trial
— CICLIBIOMEOfficial title:
A Study of the Association of the Gut and Tumor Microbiome With Disease and Treatment Outcome of CDK4/6 Inhibitors in Hormone Receptor-positive HER2-negative Breast Cancer
Ciclibiome is a prospective study including BC patients starting treatment with a CDK4/6 inhibitor (in the metastatic and in the adjuvant setting). This study will focus on the interplay between the gut microbiome (its composition and evolution during treatment), circulating immune, metabolic and cytokine biomarkers (before and during treatment), and response outcomes to the CDK4/6 inhibitor. The main aim of the study is to highlight the existence of a microbial, immune and/or metabolic biomarker of response to CDK4/6 inhibition in BC, assessable by a stool or blood sample examination. Ultimately, this will allow to study new potential combination partners for CDK4/6 inhibitors in escalation trials for poor prognosis patients.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2030 |
Est. primary completion date | November 15, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | * Cohort of metastatic HR-positive HER2-negative breast cancer : Inclusion Criteria: Patients that respond to each of these criteria can be included : - Diagnosis of previously untreated HR+ HER2- advanced breast cancer (defined as locally advanced and unresectable, or metastatic). HR+ defined as positive estrogen receptors as per local laboratory testing. HER2- defined as negative ISH test or an IHC status of 0 or 1+ as per local laboratory testing. - Planned first-line treatment with an endocrine therapy (aromatase inhibitor or fulvestrant) and a CDK4/6i. - Male or female = 18 years of age at the time the informed consent is signed. - Being able to provide written informed consent. - Patients with a history of early breast cancer are allowed providing systemic therapy (including adjuvant endocrine therapy) was discontinued more than 6 months ago. - Patients are willing and able to comply with the protocol for the duration of the study including sample collection. - Paraffin-embedded tumor tissue available at diagnosis of metastatic disease (inclusion to be discussed if not available). Exclusion Criteria: Patients who respond to any of these criteria are excluded : - Administration of the CDK4/6i already started. - Concurrent or previous non breast-related malignancy in the last 3 years prior to the start of the study treatment (with the exception of a history of adequately treated cervical carcinoma in situ or non-melanoma skin cancer). - Treatment or chronic prevention of an infection through oral or intravenous antibiotic administered less than 1 month ago. History of unique antibiotic administration as prophylaxis for an invasive procedure is allowed. - Active disease requiring treatment with an immunomodulatory agent. Low dose oral corticosteroids (equivalent to 8 mg or less of prednisone) or topical corticosteroids are allowed. - Serological positivity for human immunodeficiency virus (HIV) or hepatitis C (HCV). - Known active hepatitis. - Active inflammatory bowel disease or documented malabsorption. - Alcohol consumption (>3 glasses/day). - Cohort of early HR-positive HER2-negative breast cancer at high risk of relapse : Inclusion criteria : Patients that respond to each of these criteria can be included : - Early HR+ HER2- node-positive breast cancer considered at high risk of relapse (= 4 positive lymph nodes, or 1-3 positive lymph nodes and either or both grade 3 or tumor size > 5 cm). HR+ defined as positive estrogen receptors as per local laboratory testing. HER2- defined as negative ISH test or an IHC status of 0 or 1+ as per local laboratory testing. - Planned adjuvant treatment with a CDK4/6i, in combination with an endocrine therapy (aromatase inhibitor or tamoxifen, with or without LHRH agonists). - Male or female = 18 years of age at the time the informed consent is signed. - Being able to provide written informed consent. - Patients are willing and able to comply with the protocol for the duration of the study including sample collection. - Paraffin-embedded tumor tissue available at diagnosis of the disease or at surgical resection (inclusion to be discussed if not available). Exclusion criteria : Patients who respond to any of these criteria are excluded : - Administration of the CDK4/6i already started. Ongoing administration of the endocrine therapy before study inclusion is allowed. - Concurrent or previous non breast-related malignancy in the last 3 years prior to the start of the study treatment (with the exception of a history of adequately treated cervical carcinoma in situ or non-melanoma skin cancer). - Treatment or chronic prevention of an infection through oral or intravenous antibiotic administered less than 1 month ago. History of unique antibiotic administration as prophylaxis for an invasive procedure is allowed. - Active disease requiring treatment with an immunomodulatory agent. Low dose oral corticosteroids (equivalent to 8 mg or less of prednisone) or topical corticosteroids are allowed. - Serological positivity for human immunodeficiency virus (HIV) or hepatitis C (HCV). - Known active hepatitis. - Active inflammatory bowel disease or documented malabsorption. - Alcohol consumption (>3 glasses/day). |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques universitaires Saint-Luc | Brussels | |
Belgium | Institut Jules Bordet | Brussels |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Jules Bordet Institute |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pre-treatment gut microbiome composition | The pre-treatment composition of the gut microbiome is defined by 16S rRNA sequencing of the stool samples collected at study inclusion. | at study inclusion | |
Primary | Pre-treatment gut metabolic profile | The pre-treatment gut metabolic profile is defined by mass spectometry on the stool samples collected at study inclusion. | at study inclusion | |
Primary | Pre-treatment circulating immune population profile | The pre-treatment circulating immune population profile is defined by FACS cytometry on the blood samples collected at study inclusion. | at study inclusion | |
Primary | Pre-treatment circulating metabolic profile | The pre-treatment circulating metabolic profile is defined by mass spectometry on the plasma samples collected at study inclusion. | at study inclusion | |
Secondary | On-treatment gut microbiome composition | The on-treatment composition of the gut microbiome is defined by 16S rRNA sequencing of the stool samples collected at study inclusion. | at 3 months, 6 months, 1 year, 2 years, 5 years | |
Secondary | On-treatment gut metabolic profile | The on-treatment gut metabolic profile is defined by mass spectometry on the stool | at 3 months, 6 months, 1 year, 2 years, 5 years | |
Secondary | On-treatment circulating immune population profile | The on-treatment circulating immune population profile is defined by FACS cytometry on the blood samples collected at study inclusion. | at 3 months, 6 months, 1 year, 2 years, 5 years | |
Secondary | On-treatment circulating metabolic profile | The on-treatment circulating metabolic profile is defined by mass spectometry on the plasma samples collected at study inclusion. | at 3 months, 6 months, 1 year, 2 years, 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |